Marshall Wace
DRIO icon

Marshall Wace’s DarioHealth DRIO Stock Holding History

Marshall Wace’s Portfolio DRIO Stock Details DRIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,109
Closed -$95K – 2762
2022
Q4 		$95K Sell
1,109
-2,782
-71% -$250K ﹤0.01% 2793
2022
Q3 		$360K Buy
3,891
+1,171
+43% +$126K ﹤0.01% 2875
2022
Q2 		$335K Buy
+2,720
New +$319K ﹤0.01% 2983

Other funds holding DRIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $2.55B AUM 104.35% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
AWAM
Appian Way Asset Management New York $558M AUM 1.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Marshall Wace's DRIO Position: Q1 2023 in Review

Marshall Wace sold out of DarioHealth (DRIO) in Q1 2023, closing a stake of 1,109 shares — an estimated $95K sold.

Marshall Wace first reported a position in DRIO in Q2 2022 and held it in 3 quarters. The position peaked at $360K in Q3 2022. 46 funds tracked by Wall St. Rank hold DRIO as of Q1 2023.

  • Marshall Wace reported no remaining DarioHealth position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 1,109 DarioHealth shares in Q1 2023, an estimated $95K.
  • Marshall Wace first reported a position in DarioHealth in Q2 2022 and held it in 3 quarters.
  • Marshall Wace's DarioHealth position peaked at $360K in Q3 2022.
  • 46 funds tracked by Wall St. Rank held DarioHealth as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.